AAV-SLB101 is a rationally designed capsid developed for enhanced skeletal muscle, cardiac tropism, and reduced biodistribution to the liver.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that ...
Earlier this morning, REGENXBIO released financial and operating results for the third quarter ended September 30, 2025. Today's conference call will include forward-looking statements regarding our ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback